BioPharma Credit PLC (BPCR) - Total Assets
Based on the latest financial reports, BioPharma Credit PLC (BPCR) holds total assets worth $1.16 Billion USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioPharma Credit PLC - Total Assets Trend (2017–2024)
This chart illustrates how BioPharma Credit PLC's total assets have evolved over time, based on quarterly financial data. Also see market cap of BioPharma Credit PLC for the company's overall valuation and market capitalisation.
BioPharma Credit PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
BioPharma Credit PLC's total assets of $1.16 Billion consist of 3.1% current assets and 96.9% non-current assets. Review BioPharma Credit PLC (BPCR) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.5% |
| Accounts Receivable | $31.80 Million | 2.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how BioPharma Credit PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest BioPharma Credit PLC stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioPharma Credit PLC's current assets represent 3.1% of total assets in 2024, a decrease from 38.5% in 2017.
- Cash Position: Cash and equivalents constituted 0.5% of total assets in 2024, down from 37.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 2.7% of total assets.
BioPharma Credit PLC Competitors by Total Assets
Key competitors of BioPharma Credit PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sprott Physical Gold Trust
TO:PHYS
|
Canada | CA$14.74 Billion |
|
DWS Group GmbH & Co. KGaA
XETRA:DWS
|
Germany | €11.78 Billion |
|
KBC Ancora
BR:KBCA
|
Belgium | €3.63 Billion |
|
Anxin Trust Co Ltd
SHG:600816
|
China | CN¥26.40 Billion |
|
CI Financial Corp
TO:CIX
|
Canada | CA$11.01 Billion |
|
Norte Grande
SN:NORTEGRAN
|
Chile | CL$2.96 Billion |
|
Sprott Inc.
TO:SII
|
Canada | CA$720.71 Million |
|
Bure Equity AB
ST:BURE
|
Sweden | Skr18.07 Billion |
BioPharma Credit PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.87 | 21.50 | 2.04 |
| Quick Ratio | 7.87 | 21.50 | -0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $51.48 Million | $70.70 Million | $32.64 Million |
BioPharma Credit PLC - Advanced Valuation Insights
This section examines the relationship between BioPharma Credit PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.92 |
| Asset Growth Rate (YoY) | -11.6% |
| Total Assets | $1.20 Billion |
| Market Capitalization | $1.11 Billion USD |
Valuation Analysis
Near Book Valuation: The market values BioPharma Credit PLC's assets close to their book value (0.92x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: BioPharma Credit PLC's assets decreased by 11.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioPharma Credit PLC (2017–2024)
The table below shows the annual total assets of BioPharma Credit PLC from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.20 Billion | -11.58% |
| 2023-12-31 | $1.36 Billion | -0.53% |
| 2022-12-31 | $1.36 Billion | -0.48% |
| 2021-12-31 | $1.37 Billion | -1.27% |
| 2020-12-31 | $1.39 Billion | -2.85% |
| 2019-12-31 | $1.43 Billion | +2.56% |
| 2018-12-31 | $1.39 Billion | +50.54% |
| 2017-12-31 | $925.49 Million | -- |
About BioPharma Credit PLC
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.